Unipotent stem cells are the least-known type of stem cell. They are stem cells that are differentiated and limited to developing into only one type of cell or cell line. Unlike pluripotent stem cells, which could become any cell type, and multipotent stem cells, which are able to become a few different cell types, unipotent stem cells are restricted to developing into a single type of cell. Unipotent stem cells were first isolated from human umbilical cord blood in 1998, and since then have been found to exist in various tissues including bone marrow, lung, skin, and muscle. Unipotent stem cells are found most commonly in adult tissues. They possess the capacity to renew themselves and differentiate into the cell type they are predestined to become, and their differentiation is considered to be a phenotype selection from other progenitor cells in the tissue. The major benefit of using unipotent stem cells is that they can be directed into the cell type of the researcher’s choice, providing researchers with a relatively unlimited source of the cell type they need. Unipotent stem cells are the most difficult of the three major stem cell types to manipulate as their differentiation is limited, and so fewer research tools are available for this type of stem cell biology than for pluripotent and multipotent stem cells. Additionally, the potential medical applications for unipotent stem cell-based therapies are significantly narrower than those for multipotent and pluripotent stem cell research. Research into unipotent stem cells has generated great promise due to its potential use in tissue engineering and for healing diseases, such as Alzheimer’s, Parkinson’s, cancer, and diabetes. Early studies have suggested that unipotent stem cells could be used to replace cells damaged due to disease, aging, or injury, meaning unipotent stem cells could offer potential therapeutic treatments for a range of medical conditions.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States